Optimal Duration of Anticoagulant Therapy

Sam Schulman

doi:10.1055/s-0032-1333542

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2013; 39(02): 141-146
DOI: 10.1055/s-0032-1333542

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Optimal Duration of Anticoagulant Therapy

Sam Schulman

¹Division of Hematology and Thromboembolism, Department of Medicine, Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences (Hamilton General Site), McMaster University, Hamilton, Ontario, Canada

²The Karolinska Institute, Stockholm, Sweden

› Author Affiliations

Abstract

Anticoagulation is a potent therapy that can cause major and even fatal hemorrhage. Therefore, it is always necessary to balance the benefits and harms carefully. These effects differ with the diseases and patient characteristics. For many conditions, guidelines give clear recommendations regarding the duration of anticoagulation. For venous thromboembolism, there is a greater challenge to assess the net benefit of extended anticoagulation in the individual case. There are also conditions with very limited data and therefore no evidence-based recommendations on duration of treatment. This review focuses on the evaluation of (1) disease conditions as high or low risk according to the consequences of thromboembolic events, (2) the durability of the risk, and (3) the magnitude of the bleeding risk. The balancing of thrombotic versus bleeding risk is based on some typical patient scenarios. Examples of risk prediction tools are also provided.

Keywords

thromboembolism - hemorrhage - anticoagulation

Full Text

References

References
1 Lee AY, Levine MN, Baker RI , et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
2 Hansen ML, Sørensen R, Clausen MT , et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170 (16) 1433-1441
3 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87 (2) 144-152
4 Schulman S, Beyth RJ, Kearon C, Levine MN. American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6) (Suppl): 257S-298S
5 Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34 (7) 1710-1716
6 Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41 (12) 2860-2866
7 Donzé J, Clair C, Hug B , et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125 (8) 773-778
8 Schulman S, Beyth R. Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J 2005; 7 (Suppl C): C34-C40
9 White RH, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S. National Consortium of Anticoagulation Clinics. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med 1996; 156 (11) 1197-1201
10 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease. Chest 2008; 133 (6) (Suppl): 454S-545S
11 Schulman S, Lindmarker P, Holmström M , et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (4) 734-742
12 Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147 (11) 766-774
13 Kearon C, Akl EA, Comerota AJ , et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e419S-e494S
14 Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98 (5) 980-987
15 Holbrook A, Schulman S, Witt DM , et al. American College of Chest Physicians. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e152S-e184S
16 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 (11) 893-900
17 Kearon C, Ginsberg JS, Kovacs MJ , et al. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349 (7) 631-639
18 Ridker PM, Goldhaber SZ, Danielson E , et al. PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348 (15) 1425-1434
19 Schulman S, Eriksson H, Goldhaber S , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011; 9 (Suppl. 02) 731-732 (Abstr. O-Thu-033)
20 Palareti G, Cosmi B, Legnani C , et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355 (17) 1780-1789
21 Verhovsek M, Douketis JD, Yi Q , et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149 (7) 481-490 , W94
22 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121 (14) 1630-1636
23 Rodger MA, Kahn SR, Wells PS , et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (5) 417-426
24 Tosetto A, Iorio A, Marcucci M , et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10 (6) 1019-1025
25 Schulman S. Duration of Anticoagulation Study Group. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Wien Med Wochenschr 1999; 149 (2–4) 66-69
26 Connolly SJ, Ezekowitz MD, Yusuf S , et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
27 Granger CB, Alexander JH, McMurray JJ , et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
28 Patel MR, Mahaffey KW, Garg J , et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
29 Bauersachs R, Berkowitz SD, Brenner B , et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
30 Schulman S, Kakkar AK, Schellong S , et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Proceedings of American Society of Hematology Conference, San Diego 2011:Abstr 205
31 Schulman S, Baanstra D, Eriksson H , et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011; 9: 22(Abstr. O-Mo-037)
32 You JJ, Singer DE, Howard PA , et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e531S-e575S
33 Mitchell LB. CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol 2011; 27 (1) 91-97
34 Bishara R, Telman G, Bahouth F, Lessick J, Aronson D. Transient atrial fibrillation and risk of stroke after acute myocardial infarction. Thromb Haemost 2011; 106 (5) 877-884
35 Calkins H, Brugada J, Packer DL , et al. Heart Rhythm Society; European Heart Rhythm Association; European Cardiac Arrhythmia Society; American College of Cardiology; American Heart Association; Society of Thoracic Surgeons. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 2007; 9 (6) 335-379
36 Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e576S-e600S
37 Vandvik PO, Lincoff AM, Gore JM , et al. American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e637S-e668S
38 Ageno W, Dentali F, Squizzato A , et al. Evidence and clinical judgment: treatment of cerebral vein thrombosis. Thromb Haemost 2010; 103 (6) 1109-1115
39 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 (9) 578-589